- Trials with a EudraCT protocol (90)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
90 result(s) found for: Memory B Cell.
Displaying page 1 of 5.
EudraCT Number: 2006-002358-31 | Sponsor Protocol Number: LTR138 | Start Date*: 2006-09-11 |
Sponsor Name:RIVM | ||
Full Title: Specific B-cell Memory After a Single Dose or Booster MenC Conjugate Vaccination: a Pilot Study in Adults | ||
Medical condition: Bacterial meningitis is caused by several pathogens such as Hib, Streptococcus pneumoniae and MenC. A MenC conjugate vaccination was introduced into the National Vaccination Program at the age of 1... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-005581-19 | Sponsor Protocol Number: 719_OPBG_2014 | Start Date*: 2014-07-31 |
Sponsor Name:Bambino Gesù Children’s Hospital | ||
Full Title: Immune memory to HPV induced by Gardasil in girls and boys | ||
Medical condition: Healthy subjects undergoing voluntary vaccination | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: IT (Temporarily Halted) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003476-35 | Sponsor Protocol Number: V59P16 | Start Date*: 2007-08-20 |
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l | ||
Full Title: A Phase II, Single Centre, Open-label, Randomized Study to Investigate Meningococcal Serogroup A, C, W-135 and Y Saccharide Specific B Cell Response to a Primary and a Booster Course of the Novarti... | ||
Medical condition: The Novartis Meningococcal A, C, W-135 and Y Vaccine is intended for prevention of meningitidis and/or septicemia caused by Neisseria meningitidis serogroups A, C, W-135 and Y. | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-002378-37 | Sponsor Protocol Number: LIS/IMM138 | Start Date*: 2008-12-23 |
Sponsor Name:National Institute of Health and the Environment (RIVM) | ||
Full Title: The longitudinal kinetics of long term cellular memory immunity against Bordetella pertussis in Dutch 8-9 years old children after ACV booster vaccination. | ||
Medical condition: Whooping cough is a respiratory disease caused by Bordetella pertussis. Young infants are mostly at risk, but older children are the main source of infection. Since the incidence of whooping cough... | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000937-15 | Sponsor Protocol Number: HO161 | Start Date*: 2022-08-25 | |||||||||||
Sponsor Name:UMCG | |||||||||||||
Full Title: A phase II non-inferiority design study comparing point-of-care produced CAR T-cell to commercial CAR T-cells in patients with relapsed/refractory Non-Hodgkin Lymphoma | |||||||||||||
Medical condition: B-Cell Non Hodgkin Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001864-50 | Sponsor Protocol Number: IIV-268 | Start Date*: 2013-07-22 |
Sponsor Name:National Institute for Public Health and the Environment (RIVM, the Netherlands) | ||
Full Title: Long-term memory immunity against Bordetella pertussis in children 9 years of age who have been vaccinated with acellular pertussis vaccines: effect of an extra preadolescent acellular booster vacc... | ||
Medical condition: The vaccine administered in this study is used to prevent pertussis caused by the bacterium Bordetella pertussis | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004099-31 | Sponsor Protocol Number: 116811 | Start Date*: 2016-07-26 | |||||||||||
Sponsor Name:Glaxosmithkline Biologicals | |||||||||||||
Full Title: Long-term persistence of immunity to hepatitis B in adults vaccinated 20 to 30 years ago with Engerix™-B. | |||||||||||||
Medical condition: Healthy volunteers (immunisation against infection caused by all known subtypes of hepatitis B virus). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005355-32 | Sponsor Protocol Number: IIV-275 | Start Date*: 2014-03-06 |
Sponsor Name:National Institute for Public Health and the Environment (RIVM, the Netherlands) | ||
Full Title: Memory response against Bordetella pertussis in adults: immunological effects of an acellular pertussis booster vaccination | ||
Medical condition: The vaccine administered in this study is used to prevent pertussis caused by the bacterium Bordetella pertussis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003850-25 | Sponsor Protocol Number: PXVX-VC-200-006 | Start Date*: 2018-12-04 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:PaxVax Inc | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 4 Study to Assess the Safety and Immunogenicity of VAXCHORA (Cholera Vaccine, Live, Oral) in Children 2 to <18 Years of Age | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Prevention of cholera | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-001349-17 | Sponsor Protocol Number: OVG2007/4 | Start Date*: 2009-04-27 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: A single centre, open-label, randomised clinical trial to investigate Meningococcal serogroup A, C, W-135 and Y saccharide specific B cell response to a primary and a booster dose of the Meningococ... | |||||||||||||
Medical condition: The Novartis Meningococcal A, C, W-135 and Y vaccine is intended for prevention of meningitis and/or septicemia caused by Neisseria meningitidis serogroups A, C, W-135 and Y. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000732-28 | Sponsor Protocol Number: M14P5E1 | Start Date*: 2006-04-03 |
Sponsor Name:Chiron S.r.l. | ||
Full Title: A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C saccharide component of Chiron’s Meningococcal C Conjugate Vaccine (Menjugate®) Administered ... | ||
Medical condition: Healthy subjects without known medical conditions will be vaccinated against Neisseria meningitidis serogroup C. Active prevention of meningococcal C disease caused by Neisseria meningitidis serogr... | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-004231-24 | Sponsor Protocol Number: TBEB13 | Start Date*: 2013-03-05 |
Sponsor Name:Department für Virologie, Medizinische Universität Wien | ||
Full Title: Long-term immunity after primary vaccination against tick-borne encephalitis in the elderly | ||
Medical condition: long-term B-cell immunity against tick-borne encephalitis (TBE) in healthy volunteers who have received 3-dose primary vaccination at an age between 18 and 31 years or older than 60 years. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-002326-36 | Sponsor Protocol Number: 2016-858 | Start Date*: 2016-11-09 | ||||||||||||||||
Sponsor Name:Region Hovedstadens psykiatriske hospital | ||||||||||||||||||
Full Title: Effects of erythropoietin (EPO) on cognitive side-effects of electroconvulsive therapy (ECT) (EPO-T) | ||||||||||||||||||
Medical condition: Unipolar/bipolar depression | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005682-11 | Sponsor Protocol Number: 106068, 106072 | Start Date*: 2006-04-24 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase I/II, randomized, observer blinded study to evaluate and compare the safety, reactogenicity and immunogenicity of various formulations of the GlaxoSmithKline Biologicals’ adjuvanted 11-vale... | ||
Medical condition: Two doses vaccination in elderly subjects aged between 65 and 85 years old, in good general health and not previously immunized with the 23-valent pneumococcal polysaccharide vaccine (Pneumo 23). | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) BE (Completed) FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000442-39 | Sponsor Protocol Number: 106962 | Start Date*: 2006-04-12 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: An open, phase I/II study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ 11PCV combined with adjuvant AS02V given as a 2-dose vaccination in adults aged 18-40 years old. | ||
Medical condition: Two doses vaccination in adults subjects aged between 18 and 40 years old, in good general health and not previously immunized with the 23-valent pneumococcal polysaccharide vaccine. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-004310-33 | Sponsor Protocol Number: CAR4SAR | Start Date*: 2022-02-21 |
Sponsor Name:Dr. Antonio Pérez Martínez | ||
Full Title: A Phase I Trial of Memory T Cells Expressing an ANTI-NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults with Advanced Sarcoma | ||
Medical condition: Advanced Sarcoma | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-005645-38 | Sponsor Protocol Number: TBEB08 | Start Date*: 2008-01-17 | |||||||||||
Sponsor Name:Clinical Institute of Virology, Medical University of Vienna | |||||||||||||
Full Title: B-cell memory and humoral immune response after primary immunization against tick borne encephalitis (TBE) in the elderly | |||||||||||||
Medical condition: This study will investigate immunity against tick-borne encephalitis (TBE) following primary TBE vaccination in healthy volunteers 18-30 years or > 60 years who fulfill the local criteria for TBE v... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003588-69 | Sponsor Protocol Number: W2018.034 | Start Date*: 2019-03-07 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: The ENDURRANCE-1 Study. Exploring durable remission with rituximab in ANCA associated vasculitis | ||
Medical condition: ANCA associated vasculitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-001927-74 | Sponsor Protocol Number: SysVac01-C60P2 (PA/2008/2883) | Start Date*: 2009-01-16 |
Sponsor Name:University Hospitals Bristol NHS Foundation Trust | ||
Full Title: A PHASE II, OPEN LABEL, RANDOMISED, TWO CENTRE STUDY TO EVALUATE THE IMPORTANCE OF NATURALLY INDUCED IMMUNE REGULATION ON THE MUCOSAL IMMUNE RESPONSE TO MENINGOCOCCAL SEROGROUP B OUTER MEMBRANE VES... | ||
Medical condition: "Healthy volunteers" In this project we will establish whether naturally induced mucosal CD25+ T regulatory activity in adults and adolescents modulates the mucosal immune response to systemic Me... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001304-15 | Sponsor Protocol Number: AZGS2021005 | Start Date*: 2021-05-06 |
Sponsor Name:vzw az groeninge | ||
Full Title: COVID-19: Study of the immune response in healthy volunteers after vaccination against SARS-CoV-2 (COVID19-VAX-AZG) and monitoring of breakthrough infections after booster vaccination (COVID19-VAX-... | ||
Medical condition: immuneresponse after vaccination | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.